Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Oct;159(4):1623-1624.e3.
doi: 10.1053/j.gastro.2020.04.051. Epub 2020 Apr 27.

Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?

Affiliations
Comment

Gastrointestinal ACE2, COVID-19 and IBD: Opportunity in the Face of Tragedy?

Mayur Garg et al. Gastroenterology. 2020 Oct.
No abstract available

PubMed Disclaimer

Figures

Supplementary Figure 1
Supplementary Figure 1
Association between (A) steroids, (B) mesalamines (5-ASA), (C) thiopurines, and (D) anti-tumor necrosis factor (TNF)-α agents and mucosal ACE2 messenger RNA (mRNA) expression, angiotensin-converting enzyme 2 (ACE2) activity, and immunohistochemical (IHC) staining intensity in colonoscopic biopsies in patients with inflammatory bowel disease (IBD). No statistically significant differences were noted.
Supplementary Figure 1
Supplementary Figure 1
Association between (A) steroids, (B) mesalamines (5-ASA), (C) thiopurines, and (D) anti-tumor necrosis factor (TNF)-α agents and mucosal ACE2 messenger RNA (mRNA) expression, angiotensin-converting enzyme 2 (ACE2) activity, and immunohistochemical (IHC) staining intensity in colonoscopic biopsies in patients with inflammatory bowel disease (IBD). No statistically significant differences were noted.
Supplementary Figure 2
Supplementary Figure 2
Association between (A) steroids, (B) mesalamines (5-ASA), (C) thiopurines, and (D) anti-tumor necrosis factor (TNF)-α agents and plasma angiotensin-converting enzyme 2 (ACE2) activity in patients with inflammatory bowel disease (IBD). No statistically significant differences were noted.

Comment on

References

    1. Xiao F. Gastroenterology. 2020;158:1831–1833. - PMC - PubMed
    1. Du M. Gastroenterology. 2020;158:2298–2301. - PMC - PubMed
    1. Garg M. Gut. 2019;69:841–851. - PubMed
    1. Hashimoto T. Nature. 2012;487:477–481. - PMC - PubMed
    1. Garg M. J Renin Angiotensin Aldosterone Syst. 2015;16:559–569. - PubMed

Substances